Besides, up to 20% melanoma patients with BRAF mutations do not respond to vemurafenib treatment at all, probably due to intrinsic resistance mechanisms such as amplification of tumor promoter genes or loss of tumor suppressor genes [12]. This evidence concerns the gene BRAF and melanoma.